Coherus Shelves Eylea Biosimilar And Rules Out Early-Stage Biosimilar Development

Biosimilars Leader Coherus Marks New Era With Immuno-Oncology Play

 
• By Dean Rudge

Coherus BioSciences, a leader and innovator in the nascent US biosimilars space, has announced plans to ditch a key biosimilar opportunity and limit overall investment, in order to direct resources to immuno-oncology.

Wooden Blocks Chance Change
Coherus is "still quite open to biosimilar deals" but will will consider them carefully • Source: Shutterstock

More from Strategy

More from Business